ASAD ISMAIL: Open Payments
NPI 1144227026 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,986 in 116 payments from 19 companies in 2025. Trend: 2023 $1,363 · 2024 $2,011 · 2025 $1,986
Food & beverage: $1,805Education: $180
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 28 | $486 |
| ABBVIE INC. | 18 | $314 |
| Otsuka America Pharmaceutical, Inc. | 14 | $186 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $163 |
| E.R. Squibb & Sons, L.L.C. | 10 | $158 |
| Janssen Pharmaceuticals, Inc | 5 | $114 |
| Indivior Inc. | 4 | $81 |
| Alkermes, Inc. | 3 | $76 |
| Noven Therapeutics, LLC | 4 | $69 |
| Eisai Inc. | 3 | $65 |
Products named: VRAYLAR, UZEDY, CAPLYTA, COBENFY, REXULTI, AUSTEDO XR, INVEGA SUSTENNA, MAVYRET.
Industry payments across KY — which companies pay providers there.
